Rundu Pharma(SZ:002923)2023-04-26 16:00Dividend Distribution - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute cash dividends of 3.50 yuan per 10 shares, totaling 83,723,321.50 yuan, which represents 100% of the profit distribution[172]. - The total distributable profit for the parent company is 653,300,554.21 yuan, after accounting for a legal surplus reserve of 22,777,352.40 yuan[173]. Financial Performance - The company's operating revenue for 2022 was ¥1,372,233,917, representing a 15.32% increase compared to ¥1,189,926,867 in 2021[21]. - Net profit attributable to shareholders for 2022 was ¥155,476,936.73, an increase of 11.24% from ¥139,766,332.61 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥138,572,724.87, up 9.43% from ¥126,633,376.77 in 2021[21]. - Basic earnings per share for 2022 were ¥0.65, a 12.07% increase from ¥0.58 in 2021[21]. - Total assets at the end of 2022 were ¥2,286,349,976, reflecting a 19.74% increase from ¥1,909,438,088 at the end of 2021[21]. - Net assets attributable to shareholders increased by 7.54% to ¥1,195,984,218 from ¥1,112,155,581 in 2021[21]. - The company reported a quarterly revenue of ¥380,255,079.02 in Q4 2022, with a net profit of ¥53,853,661.06 for the same quarter[25]. - The company's formulation revenue reached 860.814 million yuan in 2022, representing a year-on-year growth of 12.28%, accounting for 62.73% of total revenue[60]. - The raw material drug manufacturing segment generated ¥502,408,912.32, which is 36.61% of total revenue, showing a year-on-year increase of 19.25%[82]. - The total cost of goods sold for 2022 was ¥600,789,626, marking a 30.94% increase from ¥458,836,067 in 2021, primarily due to expanded sales scale[87]. Risk Management - The company has outlined various risks and countermeasures in its annual report, ensuring transparency for investors[4]. - The company has confirmed that there are no significant risks affecting its production and operations during the reporting period[4]. - The company has established a comprehensive risk management framework to address potential operational challenges[4]. - The company has maintained a consistent attendance record at board meetings, with no directors missing two consecutive meetings[156]. - The company did not face any significant risks during the reporting period, as confirmed by the supervisory board[162]. Research and Development - The company is committed to enhancing its R&D capabilities by recruiting specialized talent and increasing investment in research and development[47]. - The company invested approximately 95.59 million yuan in R&D in 2022, accounting for 6.97% of its revenue, continuing a trend of significant investment in innovation[64]. - The company has a research team of over 200 personnel, with more than 80% holding bachelor's degrees or higher, and approximately 11.81% holding doctoral or master's degrees[63]. - The company is actively involved in the development of new drugs and technologies to meet market demands and improve patient outcomes[140]. - The company has established a wholly-owned R&D subsidiary in Wuhan, enhancing its research capabilities and infrastructure[69]. Market Position and Strategy - The pharmaceutical manufacturing industry is a strategic sector crucial for national health and economic development, with significant growth achieved since the 13th Five-Year Plan[32]. - The company has achieved vertical integration in the production of antihypertensive drugs, leading in domestic market supply of certain raw materials[38]. - The company is expanding its international market presence, with products sold in Europe, the USA, Japan, South Korea, and actively exploring markets in the Middle East, South Asia, Southeast Asia, and South America[50]. - The company aims to improve the clinical specialty capabilities of county-level hospitals, which is expected to increase the usage of specialized drugs and medical consumables[46]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[146]. Governance and Management - The company has a robust governance structure in place, with all board members present for the report's approval[4]. - The company has established a clear governance structure with independent directors and management, ensuring effective oversight and decision-making[134]. - The company has a strong leadership team with Chen Xinmin serving as Chairman since October 2018, bringing extensive experience in the pharmaceutical industry[138]. - The company has independent directors who received CNY 9.47 million each during the reporting period[154]. - The company has a total of 12 directors and supervisors, with varying remuneration levels based on their roles and responsibilities[153]. Compliance and Internal Control - The company is committed to maintaining compliance with regulatory standards and has detailed its adherence to relevant accounting principles[13]. - The company maintains a robust internal control system, with no significant defects identified in financial and non-financial reporting controls for 2022[186]. - The internal control self-assessment report indicates that 100% of the total assets and operating income of the evaluated units are included in the consolidated financial statements[189]. - The company recognizes the importance of compliance with laws and regulations to avoid penalties and operational disruptions[190]. - The company has established a comprehensive governance framework and effectively executed it, with no identified need for rectification during the self-inspection process[192]. Employee and Training - The total number of employees at the end of the reporting period is 1,891, with 1,202 in the parent company and 154 in major subsidiaries[163]. - The company has established a comprehensive training program, focusing on both professional and managerial talent development, with various training initiatives conducted[168]. - The employee composition includes 1,015 production personnel, 215 sales personnel, 527 technical personnel, 30 financial personnel, and 104 administrative personnel[163]. - The total number of employees with a master's degree or above is 48, while those with a bachelor's degree are 509, and those with a diploma or below are 1,343[163]. Environmental Compliance - The company strictly adheres to environmental protection policies, with wastewater and air emissions meeting regulatory standards[196]. - The wastewater discharge limits were relaxed by 200% after obtaining a new discharge permit in May 2022[196]. - The company’s noise emissions comply with the Class 3 standards of the Industrial Enterprise Boundary Noise Emission Standards[197]. - The company has implemented online monitoring devices at major discharge points, connected to environmental authorities[198]. - Hazardous waste management follows national regulations, ensuring proper storage, transfer, and disposal[200].